Associated Genetic Biomarkers
NCI Definition: A diffuse glial tumor which infiltrates the brain extensively, involving more than two lobes. It is frequently bilateral and often extends to the infratentorial structures, even to the spinal cord. It is probably of astrocytic origin, although GFAP expression may be scant or absent. (Adapted from WHO.) 
There are 2 clinical trials for gliomatosis cerebri, of which 2 are open and 0 are completed or closed. Of the trials that contain gliomatosis cerebri as an inclusion criterion, 1 is phase 2 (1 open) and 1 is phase 3 (1 open).
Deficient, MLH1, and MSH2 are the most frequent gene inclusion criteria for gliomatosis cerebri clinical trials .
Chloroquine, nivolumab, and surgery are the most common interventions in gliomatosis cerebri clinical trials.
Significant Genes in Gliomatosis Cerebri
H3F3A is an inclusion eligibility criterion in 2 clinical trials for gliomatosis cerebri, of which 2 are open and 0 are closed. Of the trials that contain H3F3A status and gliomatosis cerebri as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 3 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.